Income Statement Arch Biopartners Inc.

Equities

ACHFF

CA03938C1041

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 20:42:25 13/01/2026 GMT			5-day change	1st Jan Change
0.9743 ^USD	-2.12%		+5.70%	+10.29%

12-16	Arch Biopartners Says Toronto's St Michael's Hospital Cleared to Participate in Phase II Trial Related To Kidney Injury	MT
12-16	Arch Biopartners Inc. Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide	CI

d7548536bb54748312948f4457.GV7-rlCy0CHfbz6U6m7q_XR4-q9frlXSJM_aoPV1YRs.UTuc2xbXnHaHIHulsBvZj0Upye4q6SKHXffu6q9YB050FpiDJeXlUbE-TQ

Published financial data: ARCH BIOPARTNERS INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: September	2020	2021	2022	2023	2024
Revenues	67.89K	3.89M	965K	1.98M	2.12M
Total Revenues	67.89K	3.89M	965K	1.98M	2.12M
Cost of Goods Sold, Total	2.19M	4.04M	1.47M	2.11M	3.78M
Gross Profit	-2.12M	-150K	-503K	-129K	-1.66M
Selling General & Admin Expenses, Total	529K	560K	469K	809K	947K
Stock-Based Compensation (IS)	1.73M	110K	24.98K	1.96M	853K
Other Operating Expenses, Total	2.26M	670K	494K	2.77M	1.8M
Operating Income	-4.38M	-819K	-997K	-2.9M	-3.46M
Interest Expense, Total	-176K	-273K	-309K	-359K	-389K
Interest And Investment Income	-	-	-	16.53K	4.07K
Net Interest Expenses	-176K	-273K	-309K	-342K	-385K
Currency Exchange Gains (Loss)	5.43K	-4.86K	-18.49K	11.9K	15.94K
Other Non Operating Income (Expenses)	-79K	-72.16K	-82.93K	-100K	-95.31K
EBT, Excl. Unusual Items	-4.63M	-1.17M	-1.41M	-3.33M	-3.92M
Other Unusual Items	-	-	-	-	-
EBT, Incl. Unusual Items	-4.63M	-1.17M	-1.41M	-3.33M	-3.92M
Earnings From Continuing Operations	-4.63M	-1.17M	-1.41M	-3.33M	-3.92M
Net Income to Company	-4.63M	-1.17M	-1.41M	-3.33M	-3.92M
Net Income - (IS)	-4.63M	-1.17M	-1.41M	-3.33M	-3.92M
Net Income to Common Incl Extra Items	-4.63M	-1.17M	-1.41M	-3.33M	-3.92M
Net Income to Common Excl. Extra Items	-4.63M	-1.17M	-1.41M	-3.33M	-3.92M
Per Share Items
Net EPS - Basic	-0.08	-0.02	-0.02	-0.05	-0.06
Basic EPS - Continuing Operations	-0.08	-0.02	-0.02	-0.05	-0.06
Basic Weighted Average Shares Outstanding	59.92M	61.32M	62.16M	62.47M	63.38M
Net EPS - Diluted	-0.08	-0.02	-0.02	-0.05	-0.06
Diluted EPS - Continuing Operations	-0.08	-0.02	-0.02	-0.05	-0.06
Diluted Weighted Average Shares Outstanding	59.92M	61.32M	62.16M	62.47M	63.38M
Normalized Basic EPS	-0.05	-0.01	-0.01	-0.03	-0.04
Normalized Diluted EPS	-0.05	-0.01	-0.01	-0.03	-0.04
Supplemental Items
EBITA	-4.38M	-819K	-997K	-2.9M	-3.46M
EBIT	-4.38M	-819K	-997K	-2.9M	-3.46M
Normalized Net Income	-2.89M	-731K	-880K	-2.08M	-2.45M
Interest on Long-Term Debt	176K	172K	205K	197K	179K
Supplemental Operating Expense Items
Advertising Expense	-	-	-	-	-
Marketing Expenses	60.5K	41.06K	19.73K	7.19K	8.42K
Selling and Marketing Expenses	60.5K	41.06K	19.73K	7.19K	8.42K
General and Administrative Expenses	258K	297K	241K	382K	395K
Research And Development Expense From Footnotes	1.96M	3.78M	1.27M	1.94M	3.7M
Stock-Based Comp., Other (Total)	1.73M	110K	24.98K	1.96M	853K
Total Stock-Based Compensation	1.73M	110K	24.98K	1.96M	853K

Fiscal Period: September	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	654K	448K	506K	831K	2.97K
Short Term Investments	-	-	-	-	-
Total Cash And Short Term Investments	654K	448K	506K	831K	2.97K
Accounts Receivable, Total	-	1.85M	-	-	725K
Other Receivables	61K	349K	87.23K	297K	175K
Total Receivables	61K	2.2M	87.23K	297K	899K
Prepaid Expenses	26.62K	19.32K	28.06K	43.03K	33.33K
Total Current Assets	741K	2.67M	622K	1.17M	936K
Total Assets	741K	2.67M	622K	1.17M	936K
Liabilities
Accounts Payable, Total	943K	962K	489K	393K	2.35M
Accrued Expenses, Total	276K	425K	190K	172K	42.92K
Short-term Borrowings	-	1.8M	-	1.71M	2.27M
Current Portion of Long-Term Debt	-	-	2.1M	2.6M	500K
Unearned Revenue Current, Total	-	-	-	1.1M	118K
Total Current Liabilities	1.22M	3.19M	2.78M	5.98M	5.28M
Long-Term Debt	3.39M	3.36M	2.31M	704K	-
Total Liabilities	4.61M	6.55M	5.09M	6.68M	5.28M
Common Stock, Total	13.71M	14.76M	15.55M	15.88M	17.42M
Additional Paid In Capital	4.57M	4.68M	4.7M	6.66M	7.51M
Retained Earnings	-22.15M	-23.32M	-24.72M	-28.05M	-31.97M
Comprehensive Income and Other	-	-	-	-	2.69M
Total Common Equity	-3.87M	-3.88M	-4.47M	-5.51M	-4.35M
Total Equity	-3.87M	-3.88M	-4.47M	-5.51M	-4.35M
Total Liabilities And Equity	741K	2.67M	622K	1.17M	936K
Supplemental Items
ECS Total Shares Outstanding on Filing Date	61.36M	61.36M	62.4M	62.76M	64.94M
ECS Total Common Shares Outstanding	60.78M	61.96M	62.33M	62.6M	64.65M
Book Value / Share	-0.06	-0.06	-0.07	-0.09	-0.07
Tangible Book Value	-3.87M	-3.88M	-4.47M	-5.51M	-4.35M
Tangible Book Value Per Share	-0.06	-0.06	-0.07	-0.09	-0.07
Total Debt	3.39M	5.16M	4.41M	5.02M	2.77M
Net Debt	2.74M	4.72M	3.91M	4.18M	2.77M
Account Code - Inventory Valuation	3	3	3	3	3

Fiscal Period: September	2020	2021	2022	2023	2024
Net Income	-4.63M	-1.17M	-1.41M	-3.33M	-3.92M
Other Operating Activities, Total	2.72M	-1.81M	1.89M	3.09M	1.59M
Cash from Operations	-1.9M	-2.98M	479K	-234K	-2.33M
Short Term Debt Issued, Total	-	2.2M	-	-	-
Long-Term Debt Issued, Total	500K	-	-	1.5M	350K
Total Debt Issued	500K	2.2M	-	1.5M	350K
Short Term Debt Repaid, Total	-	-425K	-	-	-
Long-Term Debt Repaid, Total	-12K	-45.5K	-791K	-1.07M	-210K
Total Debt Repaid	-12K	-470K	-791K	-1.07M	-210K
Issuance of Common Stock	1.67M	1.05M	370K	128K	1.36M
Other Financing Activities, Total	-	-	-	-	-
Cash from Financing	2.16M	2.78M	-421K	559K	1.5M
Net Change in Cash	253K	-205K	58.11K	325K	-828K
Supplemental Items
Cash Interest Paid	-	74.35K	79.11K	2.59K	2.64K
Levered Free Cash Flow	-140K	-2.54M	606K	684K	-1.29M
Unlevered Free Cash Flow	-30.07K	-2.37M	799K	909K	-1.05M
Change In Net Working Capital	-979K	1.96M	-1.4M	-761K	-256K
Net Debt Issued / Repaid	488K	1.73M	-791K	431K	140K

Fiscal Period: September	2020	2021	2022	2023	2024
Profitability
Return on Assets	-347.68	-30.04	-37.88	-201.92	-205.03
Return on Total Capital	2.39K	-127.43	-101.86	656.48	208.54
Return On Equity %	142.31	30.18	33.71	66.67	79.54
Return on Common Equity	142.31	30.18	33.71	66.67	79.54
Margin Analysis
Gross Profit Margin %	-3.13K	-3.85	-52.13	-6.5	-78.05
SG&A Margin	779.13	14.41	48.64	40.78	44.61
EBITA Margin %	-6.45K	-21.08	-103.36	-145.99	-162.86
EBIT Margin %	-6.45K	-21.08	-103.36	-145.99	-162.86
Income From Continuing Operations Margin %	-6.82K	-30.1	-145.94	-167.71	-184.76
Net Income Margin %	-6.82K	-30.1	-145.94	-167.71	-184.76
Net Avail. For Common Margin %	-6.82K	-30.1	-145.94	-167.71	-184.76
Normalized Net Income Margin	-4.26K	-18.81	-91.21	-104.82	-115.47
Levered Free Cash Flow Margin	-206.7	-65.3	62.8	34.51	-61.01
Unlevered Free Cash Flow Margin	-44.29	-60.9	82.84	45.81	-49.54
Asset Turnover
Asset Turnover	0.09	2.28	0.59	2.21	2.01
Short Term Liquidity
Current Ratio	0.61	0.84	0.22	0.2	0.18
Quick Ratio	0.59	0.83	0.21	0.19	0.17
Operating Cash Flow to Current Liabilities	-1.56	-0.93	0.17	-0.04	-0.44
Average Days Payable Outstanding	117.89	86.41	180.5	76.27	133.01
Long Term Solvency
Total Debt/Equity	-87.65	-133.01	-98.71	-91.04	-63.71
Total Debt / Total Capital	-709.75	402.97	-7.64K	-1.02K	-175.58
LT Debt/Equity	-87.65	-86.59	-51.73	-12.78	-
Long-Term Debt / Total Capital	-709.75	262.33	-4K	-142.6	-
Total Liabilities / Total Assets	621.8	245.5	819.16	570.45	564.69
EBIT / Interest Expense	-24.82	-3	-3.22	-8.07	-8.87
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-27.69	5.63K	-75.18	105.63	6.97
Gross Profit, 1 Yr. Growth %	51.26	-92.94	235.72	-74.35	1.18K
EBITA, 1 Yr. Growth %	128.77	-81.29	21.69	190.44	19.32
EBIT, 1 Yr. Growth %	128.77	-81.29	21.69	190.44	19.32
Earnings From Cont. Operations, 1 Yr. Growth %	121.19	-74.73	20.36	136.3	17.84
Net Income, 1 Yr. Growth %	121.19	-74.73	20.36	136.3	17.84
Normalized Net Income, 1 Yr. Growth %	121.19	-74.73	20.36	136.3	17.84
Diluted EPS Before Extra, 1 Yr. Growth %	116.48	-75.31	18.74	135.14	16.14
Total Assets, 1 Yr. Growth %	-11	259.94	-76.7	88.4	-20.11
Tangible Book Value, 1 Yr. Growth %	46.7	0.37	15.15	23.25	-21.09
Common Equity, 1 Yr. Growth %	46.7	0.37	15.15	23.25	-21.09
Cash From Operations, 1 Yr. Growth %	5.55	56.49	-116.09	-148.82	895.91
Levered Free Cash Flow, 1 Yr. Growth %	-85.93	1.71K	-123.87	12.98	-289.14
Unlevered Free Cash Flow, 1 Yr. Growth %	-96.76	7.77K	-133.76	13.72	-215.68
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-	543.44	276.97	-28.56	48.31
Gross Profit, 2 Yr. CAGR %	18.86	-67.33	-51.33	-7.2	81.48
EBITA, 2 Yr. CAGR %	22.11	-34.57	-52.28	88	86.16
EBIT, 2 Yr. CAGR %	22.11	-34.57	-52.28	88	86.16
Earnings From Cont. Operations, 2 Yr. CAGR %	23.89	-25.24	-44.85	68.64	66.87
Net Income, 2 Yr. CAGR %	23.89	-25.24	-44.85	68.64	66.87
Normalized Net Income, 2 Yr. CAGR %	23.89	-25.24	-44.85	68.64	66.87
Diluted EPS Before Extra, 2 Yr. CAGR %	20.86	-26.89	-45.85	67.09	65.26
Accounts Receivable, 2 Yr. CAGR %	-	646.45	-	-	-
Total Assets, 2 Yr. CAGR %	-6.89	78.98	-8.43	-33.75	22.68
Tangible Book Value, 2 Yr. CAGR %	111.66	21.34	7.51	19.13	-1.38
Common Equity, 2 Yr. CAGR %	111.66	21.34	7.51	19.13	-1.38
Cash From Operations, 2 Yr. CAGR %	-5.92	28.52	-49.83	-71.98	120.5
Levered Free Cash Flow, 2 Yr. CAGR %	-63.13	59.51	107.78	-48.07	46.18
Unlevered Free Cash Flow, 2 Yr. CAGR %	-82.59	59.67	415.56	-38.04	14.69
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-	-	117.41	208.01	-18.27
Gross Profit, 3 Yr. CAGR %	51.47	-53.63	-28.97	-60.68	122.78
EBITA, 3 Yr. CAGR %	33.01	-34.65	-19.54	-12.87	61.56
EBIT, 3 Yr. CAGR %	33.01	-34.65	-19.54	-12.87	61.56
Earnings From Cont. Operations, 3 Yr. CAGR %	34.45	-27.07	-12.38	-10.42	49.65
Net Income, 3 Yr. CAGR %	34.45	-27.07	-12.38	-10.42	49.65
Normalized Net Income, 3 Yr. CAGR %	34.45	-27.07	-12.38	-10.42	49.65
Diluted EPS Before Extra, 3 Yr. CAGR %	30.26	-28.82	-14.06	-11.66	48.02
Accounts Receivable, 3 Yr. CAGR %	-	-	-	-	-26.86
Total Assets, 3 Yr. CAGR %	121.8	46.13	-9.29	16.47	-29.48
Tangible Book Value, 3 Yr. CAGR %	90.06	65.06	19.24	12.52	3.85
Common Equity, 3 Yr. CAGR %	90.06	65.06	19.24	12.52	3.85
Cash From Operations, 3 Yr. CAGR %	35.82	11.47	-35.71	-50.28	-7.87
Levered Free Cash Flow, 3 Yr. CAGR %	39.29	34.97	-15.31	69.59	-20.1
Unlevered Free Cash Flow, 3 Yr. CAGR %	-8.17	33.62	-4.88	211.5	-23.7
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	12.52	-	-	-	86.57
Gross Profit, 5 Yr. CAGR %	43.77	-18.31	-3.81	-38.8	3.37
EBITA, 5 Yr. CAGR %	41.43	-3.41	-11.73	-0.28	12.54
EBIT, 5 Yr. CAGR %	41.43	-3.41	-11.73	-0.28	12.54
Earnings From Cont. Operations, 5 Yr. CAGR %	40.71	2.75	-5.86	1.98	13.38
Net Income, 5 Yr. CAGR %	40.71	2.75	-5.86	1.98	13.38
Normalized Net Income, 5 Yr. CAGR %	40.71	2.75	-5.86	1.98	13.38
Diluted EPS Before Extra, 5 Yr. CAGR %	37.06	-0.06	-8.31	0.14	11.63
Accounts Receivable, 5 Yr. CAGR %	-	-	-	-	85.23
Total Assets, 5 Yr. CAGR %	2.68	63.69	55.7	6.49	2.35
Tangible Book Value, 5 Yr. CAGR %	93.8	69.24	51.32	44.87	10.52
Common Equity, 5 Yr. CAGR %	93.8	69.24	51.32	44.87	10.52
Cash From Operations, 5 Yr. CAGR %	31.91	32.48	-8.8	-35.83	5.25
Levered Free Cash Flow, 5 Yr. CAGR %	-1.27	49.25	63.46	-7.89	5.35
Unlevered Free Cash Flow, 5 Yr. CAGR %	-26.3	48.29	83.1	-1.74	2.51